Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
The leucine metabolite beta-hydroxy-beta-methylbutyrate (HMB) prevents muscle protein degradation in cancer-induced weight loss through attenuation of the ubiquitin-proteasome proteolytic pathway. To investigate the mechanism of this effect, the action of HMB on protein breakdown and intracellular signaling leading to increased proteasome expression by the tumor factor proteolysis-inducing factor (PIF) has been studied in vitro using murine myotubes as a surrogate model of skeletal muscle. A comparison has been made of the effects of HMB and those of eicosapentaenoic acid (EPA), a known inhibitor of PIF signaling. At a concentration of 50 mumol/L, EPA and HMB completely attenuated PIF-induced protein degradation and induction of the ubiquitin-proteasome proteolytic pathway, as determined by the "chymotrypsin-like" enzyme activity, as well as protein expression of 20S proteasome alpha- and beta-subunits and subunit p42 of the 19S regulator. The primary event in PIF-induced protein degradation is thought to be release of arachidonic acid from membrane phospholipids, and this process was attenuated by EPA, but not HMB, suggesting that HMB might act at another step in the PIF signaling pathway. EPA and HMB at a concentration of 50 mumol/L attenuated PIF-induced activation of protein kinase C and the subsequent degradation of inhibitor kappaBalpha and nuclear accumulation of nuclear factor kappaB. EPA and HMB also attenuated phosphorylation of p42/44 mitogen-activated protein kinase by PIF, thought to be important in PIF-induced proteasome expression. These results suggest that HMB attenuates PIF-induced activation and increased gene expression of the ubiquitin-proteasome proteolytic pathway, reducing protein degradation.
Smith
Helen J
HJ
Pharmaceutical Sciences Research Institute, Aston University, Birmingham, United Kingdom.
Wyke
Stacey M
SM
Tisdale
Michael J
MJ
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001798:Blood Proteins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D004195:Disease Models, Animal; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D051379:Mice; D018485:Muscle Fibers, Skeletal / Q000187:drug effects* / Q000378:metabolism*; D009124:Muscle Proteins / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000201:enzymology / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011509:Proteoglycans; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D025801:Ubiquitin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014631:Valerates / Q000494:pharmacology*; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology
D001798:Blood Proteins; D009124:Muscle Proteins; D061988:Proteasome Inhibitors; D011509:Proteoglycans; D025801:Ubiquitin; D014631:Valerates; C042057:proteolysis-inducing peptide; D016718:Arachidonic Acid; C004961:beta-hydroxyisovaleric acid; D015118:Eicosapentaenoic Acid; D046988:Proteasome Endopeptidase Complex